YKL-40: A new biomarker in cardiovascular disease?

Biomarkers in Medicine

Volumn 4, Issue 4, 2010, Pages 591-600

  Mathiasen, Anders Bruun ^a   Henningsen, Kristoffer Mads Aaris ^a   Harutyunyan, Marina Jurjevna ^a   Mygind, Naja Dam ^a   Kastrup, Jens ^a  

^a Copenhagen University Hospital ^*  (Denmark)

Author keywords

biomarker; cardiovascular disease; coronary artery disease; prognosis; YKL 40

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROTEIN YKL 40; SALICYLIC ACID; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; BACTERIAL INFECTION; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INFLAMMATORY DISEASE; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; TUMOR VASCULARIZATION;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; GLYCOPROTEINS; HUMANS; LECTINS; PROGNOSIS;

ANGINA;

EID: 77955596400     PISSN: 17520363     EISSN: None     Source Type: Journal    
DOI: 10.2217/bmm.10.58     Document Type: Review

References (101)

1. Yusuf S, Reddy S, Ounpuu S, Anand S: Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 104(22), 2746-2753 (2001).
2. Yusuf S, Reddy S, Ounpuu S, Anand S: Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 104(23), 2855-2864 (2001).
3. Hansson GK: Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(16), 1685-1695 (2005).
4. Ross R: Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340(2), 115-126 (1999).
5. Koenig W, Lowel H, Baumert J, Meisinger C: C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 109(11), 1349-1353 (2004).
6. Luc G, Bard JM, Juhan-Vague I et al.: C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler. Thromb. Vasc. Biol. 23(7), 1255-1261 (2003).
7. Mueller C, Buettner HJ, Hodgson JM et al.: Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 105(12), 1412-1415 (2002).
8. Ridker PM, Stampfer MJ, Rifai N: Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 285(19), 2481-2485 (2001).
9. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P: N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293(13), 1609-1616 (2005).
10. Olsen MH, Hansen TW, Christensen MK et al.: N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur. Heart J. 28(11), 1374-1381 (2007).
11. Olsen MH, Sehestedt T, Lyngbaek S et al.: Urine albumin/creatinine ratio, high sensitivity C-reactive protein and N-terminal pro brain natriuretic peptide - three new cardiovascular risk markers - do they improve risk prediction and influence treatment? Curr. Vasc. Pharmacol. 8(1), 134-139 (2010).
12. Arnlov J, Evans JC, Meigs JB et al.: Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 112(7), 969-975 (2005).
13. Borch-Johnsen K, Feldt-Rasmussen B, Strandgaard S, Schroll M, Jensen JS: Urinary albumin excretion. An independent predictor of ischemic heart disease. Arterioscler. Thromb. Vasc. Biol. 19(8), 1992-1997 (1999).
14. Morrow DA, de Lemos JA: Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115(8), 949-952 (2007).
15. Johansen JS: Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan. Med. Bull. 53(2), 172-209 (2006)
16. Johansen JS, Williamson MK, Rice JS, Price PA: Identification of proteins secreted by human osteoblastic cells in culture. J. Bone Miner. Res. 7(5), 501-512 (1992).
17. Hakala BE, White C, Recklies AD: Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J. Biol. Chem. 268(34), 25803-25810 (1993).
18. Morrison BW, Leder P: neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 9(12), 3417-3426 (1994).
19. Shackelton LM, Mann DM, Millis AJ: Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling. J. Biol. Chem. 270(22), 13076-13083 (1995).
20. Rehli M, Krause SW, Andreesen R: Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43(2), 221-225 (1997).
21. Harvey S, Weisman M, ODell J et al.: Chondrex: new marker of joint disease. Clin. Chem. 44(3), 509-516 (1998).
22. Mohanty AK, Singh G, Paramasivam M et al.: Crystal structure of a novel regulatory 40-kDa mammary gland protein (MGP-40) secreted during involution. J. Biol. Chem. 278(16), 14451-14460 (2003).
23. Malinda KM, Ponce L, Kleinman HK, Shackelton LM, Millis AJ: Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp. Cell. Res. 250(1), 168-173 (1999)
24. Nishikawa KC, Millis AJ: gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp. Cell. Res. 287(1), 79-87 (2003)
25. Recklies AD, White C, Ling H: The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase-and protein kinase B-mediated signaling pathways. Biochem. J. 365(Pt 1), 119-126 (2002)
26. Ling H, Recklies AD: The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumour necrosis factor-a. Biochem. J. 380(Pt 3), 651-659 (2004)
27. Swirski FK, Libby P, Aikawa E et al.: Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata. J. Clin. Invest. 117(1), 195-205 (2007)
28. Libby P, Braunwald E: Braunwalds Heart Disease (8th Edition). A Textbook of Cardiovascular Medicine. Saunders/Elsevier, PA, USA (2008)
29. Baeten D, Boots AM, Steenbakkers PG et al.: Human cartilage gp-39+,CD16+ monocytes in peripheral blood and synovium: correlation with joint destruction in rheumatoid arthritis. Arthritis Rheum. 43(6), 1233-1243 (2000)
30. Kirkpatrick RB, Matico RE, McNulty DE, Strickler JE, Rosenberg M: An abundantly secreted glycoprotein from Drosophila melanogaster is related to mammalian secretory proteins produced in rheumatoid tissues and by activated macrophages. Gene 153(2), 147-154 (1995)
31. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R: Differential screening identifies genetic markers of monocyte to macrophage maturation. J. Leukoc. Biol. 60(4), 540-545 (1996)
32. Rehli M, Niller HH, Ammon C et al.: Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J. Biol. Chem. 278(45), 44058-44067 (2003)
33. Boot RG, van Achterberg TA, van Aken BE et al.: Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler. Thromb. Vasc. Biol. 19(3), 687-694 (1999)
34. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ: Serum YKL-40 and colorectal cancer. Br. J. Cancer 79(9-10), 1494-1499 (1999)
35. Cintin C, Johansen JS, Christensen IJ, Price PA, Sorensen S, Nielsen HJ: High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival. Cancer 95(2), 267-274 (2002)
36. Johansen JS, Drivsholm L, Price PA, Christensen IJ: High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer 46(3), 333-340 (2004)
37. Bi J, Lau SH, Lv ZL et al.: Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum. Pathol. 40(12), 1790-1797 (2009)
38. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der MH: Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer 106(5), 1130-1139 (2006)
39. Daugaard S, Christensen LH, Hogdall E: Markers aiding the diagnosis of chondroid tumors: an immunohistochemical study including osteonectin, bcl-2, cox-2, actin, calponin, D2-40 (podoplanin), mdm-2, CD117 (c-kit), and YKL-40. APMIS 117(7), 518-525 (2009)
40. Biggar RJ, Johansen JS, Smedby KE et al.: Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. Clin. Cancer Res. 14(21), 6974-6978 (2008)
41. Mitsuhashi A, Matsui H, Usui H et al.: Serum YKL-40 as a marker for cervical adenocarcinoma. Ann. Oncol. 20(1), 71-77 (2009)
42. Mylin AK, Rasmussen T, Johansen JS et al.: Serum YKL-40 concentrations in newly diagnosed multiple myeloma patients and YKL-40 expression in malignant plasma cells. Eur. J. Haematol. 77(5), 416-424 (2006
43. Bergmann OJ, Johansen JS, Klausen TW et al.: High serum concentration of YKL-40 is associated with short survival in patients with acute myeloid leukemia. Clin. Cancer Res. 11(24 Pt 1), 8644-8652 (2005)
44. Jensen BV, Johansen JS, Price PA: High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin. Cancer Res. 9(12), 4423-4434 (2003)
45. Yamac D, Ozturk B, Coskun U et al.: Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv. Ther. 25(8), 801-809 (2008)
46. Dupont J, Tanwar MK, Thaler HT et al.: Early detection and prognosis of ovarian cancer using serum YKL-40. J. Clin. Oncol. 22(16), 3330-3339 (2004)
47. Hogdall EV, Ringsholt M, Hogdall CK et al.: YKL-40 tissue expression and plasma levels in patients with ovarian cancer. BMC Cancer 9(8), 8 (2009)
48. Yang GF, Cai PY, Li XM, Deng HX, He WP, Xie D: Expression and clinical significance of YKL-40 protein in epithelial ovarian cancer tissues. Chin. J. Cancer 28(2), 142-145 (2009)
49. Kucur M, Isman FK, Balci C et al.: Serum YKL-40 levels and chitotriosidase activity as potential biomarkers in primary prostate cancer and benign prostatic hyperplasia. Urol. Oncol. 26(1), 47-52 (2008)
50. Johansen JS, Bojesen SE, Mylin AK, Frikke-Schmidt R, Price PA, Nordestgaard BG: Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J. Clin. Oncol. 27(4), 572-578 (2009)
51. Shao R, Hamel K, Petersen L et al.: YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28(50), 4456-4468 (2009)
52. Volck B, Johansen JS, Stoltenberg M et al.: Studies on YKL-40 in knee joints of patients with rheumatoid arthritis and osteoarthritis. Involvement of YKL-40 in the joint pathology. Osteoarthritis Cartilage 9(3), 203-214 (2001)
53. Johansen JS, Stoltenberg M, Hansen M et al.: Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatol. (Oxf.) 38(7), 618-626 (1999)
54. Johansen JS, Kirwan JR, Price PA, Sharif M: Serum YKL-40 concentrations in patients with early rheumatoid arthritis: relation to joint destruction. Scand. J. Rheumatol. 30(5), 297-304 (2001)
55. Matsumoto T, Tsurumoto T: Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin. Exp. Rheumatol. 19(6), 655-660 (2001)
56. Peltomaa R, Paimela L, Harvey S, Helve T, Leirisalo-Repo M: Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol. Int. 20(5), 192-196 (2001)
57. Zivanovic S, Rackov LP, Vojvodic D, Vucetic D: Human cartilage glycoprotein 39 - biomarker of joint damage in knee osteoarthritis. Int. Orthop. 33(4), 1165-1170 (2009)
58. Koutroubakis IE, Petinaki E, Dimoulios P et al.: Increased serum levels of YKL-40 in patients with inflammatory bowel disease. Int. J. Colorectal Dis. 18(3), 254-259 (2003) (Pubitemid 36764173)
59. Vind I, Johansen JS, Price PA, Munkholm P: Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 38(6), 599-605 (2003)
60. Myasoedova E, Gabriel SE: Cardiovascular disease in rheumatoid arthritis: a step forward. Curr. Opin. Rheumatol. 22(3), 342-347 (2010)
61. Chupp GL, Lee CG, Jarjour N et al.: A chitinase-like protein in the lung and circulation of patients with severe asthma. N. Engl. J. Med. 357(20), 2016-2027 (2007)
62. Ober C, Tan Z, Sun Y et al.: Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N. Engl. J. Med. 358(16), 1682-1691 (2008)
63. Rathcke CN, Holmkvist J, Husmoen LL et al.: Association of polymorphisms of the CHI3L1 gene with asthma and atopy: a populations-based study of 6514 Danish adults. PLoS One 4(7), E6106 (2009)
64. Hempen M, Kopp HP, Elhenicky M et al.: YKL-40 is elevated in morbidly obese patients and declines after weight loss. Obes. Surg. 19(11), 1557-1563 (2009)
65. Nielsen AR, Erikstrup C, Johansen JS et al.: Plasma YKL-40: a BMI-independent marker of Type 2 diabetes. Diabetes 57(11), 3078-3082 (2008)
66. Rathcke CN, Johansen JS, Vestergaard H: YKL-40, a biomarker of inflammation, is elevated in patients with Type 2 diabetes and is related to insulin resistance. Inflamm. Res. 55(2), 53-59 (2006)
67. Rathcke CN, Persson F, Tarnow L, Rossing P, Vestergaard H: YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with Type 1 diabetes and increases with levels of albuminuria. Diabetes Care 32(2), 323-328 (2009)
68. Gustafson B, Gogg S, Hedjazifar S, Jenndahl L, Hammarstedt A, Smith U: Inflammation and impaired adipogenesis in hypertrophic obesity in man. Am. J. Physiol. Endocrinol. Metab. DOI:10.1152/ ajpendo.00377.2009 (2009) (Epub ahead of print)
69. Spalding KL, Arner E, Westermark PO et al.: Dynamics of fat cell turnover in humans. Nature 453(7196), 783-787 (2008)
70. Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U: Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab. Res. Rev. 24(8), 595-603 (2008)
71. Mathieu P, Lemieux I, Despres JP: Obesity, inflammation, and cardiovascular risk. Clin. Pharmacol. Ther. 87(4), 407-416 (2010)
72. Johansen JS, Krabbe KS, Moller K, Pedersen BK: Circulating YKL-40 levels during human endotoxaemia. Clin. Exp. Immunol. 140(2), 343-348 (2005)
73. Kronborg G, Ostergaard C, Weis N et al.: Serum level of YKL-40 is elevated in patients with Streptococcus pneumoniae bacteremia and is associated with the outcome of the disease. Scand. J. Infect. Dis. 34(5), 323-326 (2002)
74. Hattori N, Oda S, Sadahiro T et al.: YKL-40 identified by proteomic analysis as a biomarker of sepsis. Shock 32(4), 393-400 (2009)
75. Ostergaard C, Johansen JS, Benfield T, Price PA, Lundgren JD: YKL-40 is elevated in cerebrospinal fluid from patients with purulent meningitis. Clin. Diagn. Lab. Immunol. 9(3), 598-604 (2002)
76. Nojgaard C, Host NB, Christensen IJ et al.: Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron. Artery Dis. 19(4), 257-263 (2008)
77. Wang Y, Ripa RS, Johansen JS et al.: YKL-40 a new biomarker in patients with acute coronary syndrome or stable coronary artery disease. Scand. Cardiovasc. J. 42(5), 295-302 (2008)
78. Hedegaard A, Sejersten RR, Johansen JS, Jorgensen E, Kastrup J: Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand. J. Clin. Lab. Invest. 70(2), 80-86 (2010)
79. Hogdall EV, Johansen JS, Kjaer SK, Price PA, Blaakjaer J, Hogdall CK: Stability of YKL-40 concentration in blood samples. Scand. J. Clin. Lab. Invest. 60(4), 247-251 (2000)
80. Johansen JS, Jensen HS, Price PA: A new biochemical marker for joint injury. Analysis of YKL-40 in serum and synovial fluid. Br. J. Rheumatol. 32(11), 949-955 (1993)
81. Johansen JS, Hvolris J, Hansen M, Backer V, Lorenzen I, Price PA: Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br. J. Rheumatol. 35(6), 553-559 (1996)
82. Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD, Vignon E: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: relations with disease activity and joint damage. Ann. Rheum. Dis. 60(6), 619-626 (2001)
83. Kastrup J, Johansen JS, Winkel P et al.: High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur. Heart J. 30(9), 1066-1072 (2009)
84. Kucur M, Isman FK, Karadag B, Vural VA, Tavsanoglu S: Serum YKL-40 levels in patients with coronary artery disease. Coron. Artery Dis. 18(5), 391-396 (2007)
85. Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H: Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int. J. Cardiol. 143(1), 35-42 (2009)
86. Zheng JL, Lu L, Hu J et al.: Increased serum YKL-40 and C-reactive protein levels are associated with angiographic lesion progression in patients with coronary artery disease. Atherosclerosis 210(2), 590-595 (2010).
87. Rathcke CN, Kistorp C, Raymond I et al.: Plasma YKL-40 levels are elevated in patients with chronic heart failure. Scand. Cardiovasc. J. 44(2), 92-99 (2010)
88. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366(9493), 1267-1278 (2005
89. Scirica BM, Morrow DA: Is C-reactive protein an innocent bystander or proatherogenic culprit? The verdict is still out. Circulation 113(17), 2128-2134 (2006)
90. Bonnet J, McPherson R, Tedgui A et al.: Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study. Clin. Ther. 30(12), 2298-2313 (2008)
91. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A: Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96(4), 1180-1184 (1997)
92. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA: Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92(7), 1954-1968 (1995)
93. Chung MK, Martin DO, Sprecher D et al.: C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104(24), 2886-2891 (2001)
94. Engelmann MD, Svendsen JH: Inflammation in the genesis and perpetuation of atrial fibrillation. Eur. Heart J. 26(20), 2083-2092 (2005)
95. Henningsen KM, Nilsson B, Bruunsgaard H, Chen X, Pedersen BK, Svendsen JH: Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand. Cardiovasc. J. 1-7 (2008)
96. Kallergis EM, Manios EG, Kanoupakis EM et al.: The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation. Heart 94(2), 200-204 (2008)
97. Loricchio ML, Cianfrocca C, Pasceri V et al.: Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion. Am. J. Cardiol. 99(10), 1421-1424 (2007)
98. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H: High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int. J. Cardiol. 108(3), 346-353 (2006)
99. Henningsen KM, Therkelsen SK, Johansen JS, Bruunsgaard H, Svendsen JH: Plasma YKL-40, a new biomarker for atrial fibrillation? Europace 11(8), 1032-1036 (2009)
100. Henningsen KM, Nilsson B, Johansen J, Chen X, Pehrson S, Svendsen JH: Plasma YKL-40 is elevated in patients with recurrent atrial fibrillation after catheter ablation. Inflamm. Res. 59(6), 463-1439 (2010)
101. Johansen JS, Lottenburger T, Nielsen HJ et al.: Diurnal, weekly, and long-time variation in serum concentrations of YKL-40 in healthy subjects. Cancer Epidemiol. Biomarkers Prev. 17(10), 2603-2608 (2008